Abstract
Lentiviral vectors (LVs) have been increasingly used in clinical gene therapy applications particularly due to their efficient gene transfer ability, lack of interference from preexisting viral immunity, and long-term gene expression they provide. Purity of LVs is essential in in vivo applications, for a high therapeutic benefit with minimum toxicity. Accordingly, laboratory scale production of LVs frequently involves transient cotransfection of 293T cells with packaging and transfer plasmids in the presence of CaPO4. After clearance of the cellular debris by low-speed centrifugation and filtration, lentivectors are usually concentrated by high-speed ultracentrifugation in sucrose cushion. Concentrated viral samples are then purified by anion exchange chromatography (AEX) after benzonase treatment to remove the residual cellular DNA. Here, we describe an improved practical method for LV purification using AEX, useful for experimental studies concerning gene and stem cell therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ponder KP (2001) Vectors of gene therapy. In: Kresina TF (ed) An introduction to molecular medicine and gene therapy. Wiley-Liss, Inc., New York, pp 77–112
Lundstrom K, Boulikas T (2003) Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat 2(5):471–486
Glover DJ et al (2005) Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 6(4):299–310
Hanna E et al (2017) Gene therapies development: slow progress and promising prospect. J Mark Access Health Policy 5(1):1265293
Tasyurek HM, Eksi YE, Sanlioglu AD, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S (2018) HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes. Gene Ther https://doi.org/10.1038/s41434-018-0011-1
Tasyurek HM et al (2018) Therapeutic potential of lentivirus-mediated glucagon-like peptide-1 (GLP-1) gene therapy for diabetes. Hum Gene Ther. https://doi.org/10.1089/hum.2017.180
Segura MM et al (2006) Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol Adv 24(3):321–337
Segura MM, Kamen AA, Garnier A (2011) Overview of current scalable methods for purification of viral vectors. In: OW Merten A-RM (ed) Viral vectors for gene therapy. Humana Press, Totowa, NJ, pp 89–116
Segura MM et al (2005) A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnol Bioeng 90(4):391–404
Gandara C et al (2018) Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to good manufacturing practice. Hum Gene Ther Methods 29(1):1–15
Merten OW et al (2011) Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 22(3):343–356
Slepushkin V, Chang N, Cohen R (2003) Large-scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule. Bioprocess J 2:89–95
Geraerts M et al (2005) Upscaling of lentiviral vector production by tangential flow filtration. J Gene Med 7(10):1299–1310
Cooper AR et al (2011) Highly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration. J Virol Methods 177(1):1–9
Roush DJ, Lu Y (2008) Advances in primary recovery: centrifugation and membrane technology. Biotechnol Prog 24(3):488–495
Burns JC et al (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 90(17):8033–8037
Kutner RH et al (2009) Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography. BMC Biotechnol 9:10
Transfiguracion J et al (2003) Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. Hum Gene Ther 14(12):1139–1153
Sastry L et al (2004) Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment. Hum Gene Ther 15(2):221–226
Ausubel LJ et al (2012) Production of CGMP-grade lentiviral vectors. Bioprocess Int 10(2):32–43
Yu JH, Schaffer DV (2006) Selection of novel vesicular stomatitis virus glycoprotein variants from a peptide insertion library for enhanced purification of retroviral and lentiviral vectors. J Virol 80(7):3285–3292
Rodrigues T et al (2006) Screening anion-exchange chromatographic matrices for isolation of onco-retroviral vectors. J Chromatogr B Analyt Technol Biomed Life Sci 837(1–2):59–68
Merten OW et al (2014) Manufacturing of viral vectors: Part II. Downstream processing and safety aspects. Pharm Bioprocess 2(3):237–251
Yamada K et al (2003) Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. Biotechniques 34(5):1074–1078, 1080
Scherr M et al (2002) Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. Gene Ther 9(24):1708–1714
Acknowledgments
This study is supported by grants from Akdeniz University Scientific Research Administration Division (TYL-2015-1027) and the Scientific and Technological Research Council of Turkey (TUBITAK-112S114).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media New York
About this protocol
Cite this protocol
Olgun, H.B., Tasyurek, H.M., Sanlioglu, A.D., Sanlioglu, S. (2018). High-Grade Purification of Third-Generation HIV-Based Lentiviral Vectors by Anion Exchange Chromatography for Experimental Gene and Stem Cell Therapy Applications. In: Turksen, K. (eds) Skin Stem Cells. Methods in Molecular Biology, vol 1879. Humana Press, New York, NY. https://doi.org/10.1007/7651_2018_154
Download citation
DOI: https://doi.org/10.1007/7651_2018_154
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8869-3
Online ISBN: 978-1-4939-8870-9
eBook Packages: Springer Protocols